- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02287467
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Influenza is responsible for thousands of hospitalizations and deaths each year in the United States and worldwide. One possible new treatment for the flu involves the use of IVIG, a blood product containing antibodies from people who have recovered from the flu or who have had a flu shot. The purpose of this study is to evaluate whether IVIG can reduce the severity and duration of flu in people who are hospitalized with the flu.
The study will enroll participants 18 years and older who are hospitalized with the flu. The study will enroll participants over one or more flu seasons. Regardless of the date of enrollment, each participant will be in the study for about 28 days.
At study entry (Day 0), participants will be randomly assigned to one of two groups (Arms A and B). Participants in both groups will receive standard of care (SOC) treatment for the flu, but those in Arm A will also receive one dose of IVIG and those in Arm B will receive a placebo for IVIG. Both IVIG and placebo will be given intravenously over at least 2 hours.
On Day 0, before receiving IVIG or placebo, participants will undergo a symptoms assessment, blood collection, and a nasopharyngeal (NP) swab to collect a sample of secretions from the nose and throat.
Additional study visits will occur on Days 1, 2, 3, 7, 14, and 28. Depending on the visit, participants may take part in the same study procedures that took place on Day 0. On Days 2, 14, and 28, visits for participants who are no longer hospitalized may be conducted over the phone.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Sydney, Australia
- Westmead Hospital
-
-
-
-
-
Odense, Denmark
- Odense University Hospital
-
-
-
-
-
Leeds, United Kingdom
- St James's University Hospital
-
Oxford, United Kingdom
- Churchill Hospital
-
-
-
-
California
-
San Diego, California, United States, 92103
- UCSD Antiviral Research Center (A VRC)
-
-
Colorado
-
Denver, Colorado, United States, 80204
- Denver public Health
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Minneapolis VA Medical Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10010
- Cornell CRS
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
Columbus, Ohio, United States, 43210
- Ohio State University (OSU) Wexner Medical Center
-
Dayton, Ohio, United States, 45409
- Miami Valley Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Texas
-
Dallas, Texas, United States, 75235
- UT Southwestern Medical Center
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Locally determined positive influenza test (by polymerase chain reaction [PCR] or other nucleic acid test, or by rapid antigen [Ag]) from a specimen obtained within 2 days prior to randomization
- Onset of illness no more than 7 days before randomization, defined as when the participant first experienced at least one respiratory symptom or fever
- Hospitalized (or in observation unit) for influenza, with anticipated hospitalization for more than 24 hours. Criteria for hospitalization will be up to the individual treating clinician.
- For women of child-bearing potential: willingness to abstain from sexual intercourse or use at least one form of hormonal or barrier contraception through Day 28 of the study
- Willingness to have blood and respiratory samples obtained and stored
- NEW score greater than or equal to 2 at screening (see the protocol for more information on this criterion)
Exclusion Criteria:
- Women who are pregnant or breast-feeding
- Strong clinical evidence (in the judgment of the site investigator) that the etiology of illness is primarily bacterial in origin
- Prior treatment with any investigational drug therapy within 30 days prior to screening
- History of allergic reaction to blood or plasma products (as judged by the site investigator)
- Known immunoglobulin A (IgA) deficiency
- A pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the participant at a substantially increased risk of thrombosis (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically significant monoclonal gammopathy)
- Presence of any pre-existing illness that, in the opinion of the site investigator, would place the participant at an unreasonably increased risk through participation in this study
- Participants who, in the judgment of the site investigator, will be unlikely to comply with the requirements of this protocol
- Medical conditions for which receipt of a 500 mL volume of intravenous fluid may be dangerous to the participant (e.g., decompensated congestive heart failure)
- Receiving extracorporeal membrane oxygenation (ECMO)
- Suspicion that infection is due to an influenza strain or subtype other than A(H1N1)pdm09, H3N2, or influenza B (e.g., H5N1, H7N9)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: hIVIG
Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
|
Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
|
Placebo Comparator: Arm B: Placebo
Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
|
Administered IV as 500 mL of normal saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients in Each of 6 Clinical Status Categories on Day 7
Time Frame: Assessed on Day 7
|
This is the primary outcome, a 6-category ordinal outcome ranging from death (worst) to discharged from hospital with resumption of normal activities (best).
|
Assessed on Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients in Each of 5 Clinical Status Categories on Day 3
Time Frame: Assessed on Day 3
|
5-category ordinal outcome assessed on day 3; clinical status ranges from death (worst) to discharged from the hospital (best).
|
Assessed on Day 3
|
Number of Patients in Each of 6 Clinical Status Categories on Day 3
Time Frame: Measured on Day 3
|
6-category ordinal outcome evaluated on Day 3; clinical status ranges from death (worst) to discharged from hospital with resumption of normal activities (best).
|
Measured on Day 3
|
Number of Patients With a Favorable Outcome on Day 7
Time Frame: Assessed on Day 7
|
Sliding dichotomy defined as non-ICU hospitalization or discharge if enrolled from ICU, and discharge if enrolled from the general ward.
|
Assessed on Day 7
|
Hospital Discharge
Time Frame: Measured through Day 7
|
Number of participants alive and discharged from the hospital
|
Measured through Day 7
|
Mortality
Time Frame: Measured through day 28
|
Number of participants dying through day 28.
|
Measured through day 28
|
Number of Patients Alive and Out of Hospital
Time Frame: Measured through Day 28
|
Number and percent alive and out of hospital on day 28
|
Measured through Day 28
|
Change in Viral Load
Time Frame: Day 3
|
Change in nasopharyngeal viral load from baseline to day 3
|
Day 3
|
Death or Re-hospitalization
Time Frame: Day 28
|
Number and percent of participants who died or were re-hospitalized after initial discharge
|
Day 28
|
Percent of Participants Developing Complications
Time Frame: Measured through Day 28
|
Number and percent of participants developing respiratory distress syndrome, acute renal failure, sepsis, pneumonia, enteritis, or bronchitis
|
Measured through Day 28
|
Number of Patients in Each of 6 Clinical Status Categories on Day 14
Time Frame: Measured on day 14
|
6-category ordinal outcome measured on day 14
|
Measured on day 14
|
Number of Patients Alive and Out of Hospital on Day 14
Time Frame: day 14
|
Number and percentage of participants alive and out of the hospital on Day 14
|
day 14
|
Resumption of Normal Activities by Day 14
Time Frame: day 14
|
Participants reporting resumption of normal daily activities by Day 14
|
day 14
|
Number of Patients in Each of 6 Clinical Status Categories on Day 28
Time Frame: day 28
|
6-category ordinal outcome corresponding to clinical status on day 28
|
day 28
|
Number of Influenza A-Infected Patients in Each of 6 Clinical Status Categories on Day 7
Time Frame: Day 7
|
Primary 6-category ordinal outcome for participants infected with Influenza A
|
Day 7
|
Number of Influenza B-Infected Patients in Each of 6 Clinical Status Categories on Day 7
Time Frame: Day 7
|
Primary 6-category ordinal outcome for subgroup of participants infected with influenza B
|
Day 7
|
pH1N1 Titers at Day 7
Time Frame: Day 7
|
pH1N1 hemagglutination inhibition assay (HAI) titers among participants infected with pH1N1 using A/Cal/2009 as reference virus
|
Day 7
|
H3N2 Titers at Day 7
Time Frame: Day 7
|
H3N2 HAI titers among participants infected with H3N2 using A/HongKong/2014 as reference virus
|
Day 7
|
Influenza B Titers at Day 7
Time Frame: Day 7
|
Flu B HAI titers among participants infected with influenza B using B/Phuket/2013 as reference virus
|
Day 7
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Richard T. Davey, Jr., MD, National Institute of Allergy and Infectious Diseases (NIAID)
- Study Chair: Eduardo Fernández-Cruz, MD, PhD, Hospital General Universitario Gregorio Marañon
- Study Chair: Norman P. Markowitz, MD, The Henry Ford Hospital
- Study Chair: Sarah L. Pett, MD, MBBS, DTM, MRCP (UK), University College, London
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INSIGHT 006: FLU-IVIG
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza A
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 VirusUnited States
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | OrthomyxovirdaeUnited States
-
Emergent BioSolutionsCompletedInfluenza A H3N2 | Influenza A H1N1United States, Spain, Canada, Puerto Rico
-
Butantan InstituteUniversity of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...CompletedImmunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)VaccineBrazil
-
Novartis VaccinesCompletedNovel Influenza A (H1N1) | A New Flu Virus of Swine OriginChile, Colombia, Germany, Switzerland
-
Novartis VaccinesCompletedA New Flu Virus of Swine Origin | Pandemic Influenza A (H1N1)Argentina, Netherlands
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
Ellume Pty LtdCompletedInfluenza A | Influenza BAustralia
Clinical Trials on Intravenous hyperimmune immunoglobulin (IVIG)
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela Youde... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenzaUnited States
-
Johns Hopkins UniversityTerminatedAutoimmunity | Dysmotility SyndromeUnited States
-
University of PittsburghBayer; Shadyside Hospital FoundationTerminatedClostridium Difficile-associated Diarrhea (CDAD)United States
-
University of MinnesotaNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsRecruitingCovid19 | COVID | SARS-CoV2 InfectionUnited States, Spain, Argentina, Denmark, Greece, India, Mexico, Uganda
-
Kanecia Obie ZimmermanEnrolling by invitationLong COVID | Long Covid-19 | Long Coronavirus Disease 2019 (Covid19)United States
-
University of MinnesotaCSL Behring; BriovaRx Infusion ServicesCompletedChronic Inflammatory Demyelinating PolyneuropathyUnited States
-
National Institute of Neurological Disorders and...CompletedDemyelinating Diseases | ParaproteinemiasUnited States
-
University of Texas Southwestern Medical CenterGrifols Biologicals, LLC; Dysautonomia InternationalCompletedPostural Tachycardia SyndromeUnited States
-
Assiut UniversityCompleted